• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues 2',5'-dideoxyribonucleosides

Introduction to 5'-azido-2',5'-dideoxyuridine (CAS No. 35959-37-6): A Key Intermediate in Modern Nucleoside Chemistry and Therapeutic Applications

5'-azido-2',5'-dideoxyuridine, identified by the chemical identifier CAS No. 35959-37-6, represents a significant compound in the realm of nucleoside chemistry and pharmaceutical development. This nucleoside analog has garnered considerable attention due to its unique structural features and its pivotal role as an intermediate in the synthesis of various therapeutic agents. The compound’s molecular framework, characterized by the presence of an azido group at the 5' position and deoxy modifications at the 2' and 5' positions of the uridine sugar, endows it with distinctive chemical properties that make it invaluable in medicinal chemistry.

The significance of 5'-azido-2',5'-dideoxyuridine is underscored by its application in the development of antiviral agents, particularly those targeting RNA viruses. The azido group serves as a versatile handle for further functionalization, enabling chemists to design molecules with enhanced pharmacological profiles. Recent advancements in synthetic methodologies have further highlighted the utility of this compound, facilitating its incorporation into increasingly complex drug candidates.

In recent years, 5'-azido-2',5'-dideoxyuridine has been explored as a precursor in the synthesis of modified nucleosides that exhibit improved stability and bioavailability. These modifications are critical for developing next-generation therapeutics capable of overcoming challenges posed by viral resistance and metabolic degradation. The compound’s ability to serve as a scaffold for structural diversification has opened new avenues in drug discovery, particularly in the context of RNA-dependent RNA polymerase (RdRp) inhibitors used against viruses such as influenza and hepatitis C.

One of the most compelling aspects of 5'-azido-2',5'-dideoxyuridine is its role in enabling site-specific labeling and conjugation strategies. The azido group can be selectively reduced to an amino group, allowing for further derivatization into amine-conjugated nucleosides. This capability is particularly valuable in therapeutic contexts where targeted delivery and specific interactions with biological targets are essential. For instance, researchers have leveraged this property to develop antisense oligonucleotides (ASOs) and RNA interference (RNAi) therapeutics, where precise modification of nucleoside analogs enhances efficacy and reduces off-target effects.

The pharmaceutical industry has also recognized the potential of 5'-azido-2',5'-dideoxyuridine in addressing unmet medical needs. Its incorporation into novel drug candidates has shown promise in preclinical studies, demonstrating efficacy against a range of viral infections. The compound’s structural versatility allows for fine-tuning of pharmacokinetic properties, including solubility, metabolic stability, and cell membrane permeability. These attributes are crucial for optimizing drug delivery systems and improving patient compliance.

Moreover, the synthetic pathways involving 5'-azido-2',5'-dideoxyuridine have been refined to enhance scalability and cost-effectiveness. Modern catalytic methods, including transition-metal-catalyzed azidation and reduction reactions, have streamlined the production process, making it more accessible for industrial applications. This progress underscores the compound’s importance not only in academic research but also in commercial drug development pipelines.

Recent studies have further elucidated the mechanistic aspects of 5'-azido-2',5'-dideoxyuridine derivatives in biological systems. Researchers have demonstrated that certain modifications can enhance binding affinity to viral enzymes while minimizing toxicity to host cells. These findings are critical for developing drugs with improved therapeutic indices. Additionally, computational modeling techniques have been employed to predict the behavior of these compounds within complex biological environments, aiding in rational drug design.

The future prospects of 5'-azido-2',5'-dideoxyuridine are promising, with ongoing research exploring its potential in emerging therapeutic areas such as gene therapy and immunotherapy. Its ability to serve as a building block for innovative nucleoside analogs positions it as a cornerstone in nucleoside-based drug discovery. As our understanding of molecular biology continues to evolve, compounds like CAS No. 35959-37-6 will undoubtedly play a pivotal role in shaping next-generation therapies.

• 53657-37-7(1-[3,4-dimethoxy-5-(methoxymethyl)oxolan-2-yl]-3-methylpyrimidine-2,4-dione)
• 19316-85-9(5’-Azido-(5’-deoxy)thymidine)
• 101039-96-7(2,4(1H,3H)-Pyrimidinedione,1-(3-azido-2,3-dideoxy-b-D-threo-pentofuranosyl)-)
• 61373-43-1(2'-O-Ethyluridine)
• 35959-38-7(5'-Amino-2',5'-dideoxyuridine)
• 132101-31-6(Uridine,3'-azido-2',3',5'-trideoxy-5'-(formylamino)- (9CI))
• 100898-90-6(Uridine, 3',5'-diazido-2',3',5'-trideoxy-)
• 223777-15-9(2'-O-(2-Methoxyethyl)-uridine)
• 84472-85-5(3'-Azido-2',3'-dideoxyuridine)
• 2140-76-3(2′-O-Methyluridine)